UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000007723 |
|---|---|
| Receipt number | R000008620 |
| Scientific Title | Phase 1 safety trial of bortezomib-based graft-versus-host disease prophylaxis in allogeneic hematopoietic stem cell transplantation from an HLA-mismatched unrelated donor in the Japan marrow donor program (JMDP) |
| Date of disclosure of the study information | 2012/04/15 |
| Last modified on | 2019/03/31 15:01:01 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase 1 safety trial of bortezomib-based graft-versus-host disease prophylaxis in allogeneic hematopoietic stem cell transplantation from an HLA-mismatched unrelated donor in the Japan marrow donor program (JMDP)
Acronym
Safety of bortezomib-based GVHD prophylaxis in allogeneic hematopoietic stem cell transplantation from an HLA-mismatched unrelated donor in Japan
Scientific Title
Phase 1 safety trial of bortezomib-based graft-versus-host disease prophylaxis in allogeneic hematopoietic stem cell transplantation from an HLA-mismatched unrelated donor in the Japan marrow donor program (JMDP)
Scientific Title:Acronym
Safety of bortezomib-based GVHD prophylaxis in allogeneic hematopoietic stem cell transplantation from an HLA-mismatched unrelated donor in Japan
Region
| Japan |
Condition
Condition
Adult hematological malignancies who have an indication for allogeneic stem cell transplantation
Classification by specialty
| Hematology and clinical oncology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To study safety of bortezomib-based GVHD prophylaxis after allogeneic stem cell transplantation from an HLA-mismatched unrelated donor for adult patients with hematological malignancy who lack a suitable donor.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
The incidences of dose-limiting toxicity of high-dose bortezomib (defined as DLT1) and low-dose bortezomib (defined as DLT2)
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Bortezomib is given at day 1, 4 and 7 after transplantation for GVHD prophylaxis. Three dose levels are planned (level 0: 1.0 mg/m2, level1: 1.3 mg/m2 and level2: 1.5 mg/m2) and 1.3mg/m2 (level 1) is started as the initial dose. The dose level is adjusted according to the rate of DLT. Tacrolimus is started as a 24-hour continuous intravenous infusion at a dose of 0.03 mg/kg/day from day -1. Methotrexate is given at day 1, 3, 6 and 11 after transplantation.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| 70 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1. Documented informed consent
2. PS 0 or 1
3. Patient with hematological malignancy who have an indication for allogeneic hematopoietic stem cell transplantation but lacks a suitable donor including related HLA-matched, related 1-antigen mismatched and unrelated HLA-matched donor, and both of the following two conditions 3-1 and 3-2 should be met.
3-1: Single antigen mismatch at HLA-A, B, C or DR locus (with 7/8 allele match), or single allele mismatch at HLA-A or B locus (with 7/8 allele match). Only one antigen or one allele mismatch at HLA-C locus except for severe acute GVHD high-risk mismatch combination is excluded.
3-2: One antigen and one allele mismatch at HLA-A, B, C or DR (with 6/8 allele match) except for mismatches at the same locus.
4. Normal function of major organ
Key exclusion criteria
1. Uncontrolled active infection
2. Uncontrolled CNS invasion
3. Poorly controlled insulin-treated diabetes mellitus
4. Poorly controlled hypertension
5. Patients with a severe complication including heart failure, coronary failure, acute myocardial infarction within the last 3 months, liver cirrhosis or interstitial pneumonia
6. Pregnant, nursing or possibly pregnant woman
7. Patients with severe mental disorder who are unlikely to unable to participate in the study due to a severe mental disorder
8. A history of hypersensitivity or allergy to any drugs in the conditioning regimen of this transplant
9. HIV antibody positivity
10. Peripheral neuropathy >= grade2
11. Unable to give methotrexate due to pleural effusion and ascites
12. ATG or Campath-1H containing conditioning regimen
13. Nonmyeloablative conditioning regimens, the dose intensity of which are equal to or less than that of truly mini-conditioning developed in Seattle "TBI2Gy + Fludarabine 90mg/m2"
14. Progression or relapse is expected within day 100 after transplantation
15. Other active malignancy
16. Patients with a donor-specific anti-HLA antibodyies
17. Inappropriate to participate in this study as no indication for this study judged by physician in charge.
Target sample size
6
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Takahiko Nakane |
Organization
Osaka City University, Graduate School of Medicine
Division name
Hematology
Zip code
Address
1-4-3, Asahi-machi, Abeno-ku, Osaka, Japan. 545-8585
TEL
06-6645-3881
nakane@med.osaka-cu.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Takahiko Nakane |
Organization
Osaka City University, Graduate School of Medicine
Division name
Hematology
Zip code
Address
1-4-3, Asahi-machi, Abeno-ku, Osaka, Japan. 545-8585
TEL
06-6645-3881
Homepage URL
nakane@med.osaka-cu.ac.jp
Sponsor or person
Institute
Hematology,Osaka City University, Graduate School of Medicine
Institute
Department
Personal name
Funding Source
Organization
none
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2012 | Year | 04 | Month | 15 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2012 | Year | 02 | Month | 01 | Day |
Date of IRB
| 2012 | Year | 02 | Month | 01 | Day |
Anticipated trial start date
| 2012 | Year | 10 | Month | 16 | Day |
Last follow-up date
| 2019 | Year | 03 | Month | 29 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2012 | Year | 04 | Month | 10 | Day |
Last modified on
| 2019 | Year | 03 | Month | 31 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008620
